Log in to save to my catalogue

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, doub...

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, doub...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01785450v1

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

About this item

Full title

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Publisher

England: Elsevier Ltd

Journal title

Lancet neurology, 2017-03, Vol.16 (3), p.208-216

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1G93A mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefor...

Alternative Titles

Full title

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_01785450v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01785450v1

Other Identifiers

ISSN

1474-4422,1474-4465

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(16)30399-4

How to access this item